Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an update.
Ascletis Pharma reported positive topline data from a 24-week U.S. Phase II trial of its ultra-long-acting subcutaneous depot formulation of small molecule GLP-1 receptor agonist ASC30 in obese or overweight patients. The A1 formulation delivered statistically significant, clinically meaningful placebo-adjusted weight loss of 6.3% at week 12 and 7.5% at week 16 after three once-monthly 400 mg doses, without any lead-in weekly injections.
The study also showed that ASC30 A1 maintained therapeutic drug exposure and sustained weight loss for up to four months after the final dose, supporting potential once-monthly treatment and once-quarterly maintenance regimens. Both A1 and A2 formulations demonstrated a safety and tolerability profile consistent with the GLP-1 class, with only mild to moderate adverse events and no discontinuations, positioning Ascletis as an emerging competitor in the rapidly expanding obesity drug market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biotechnology company listed in Hong Kong that focuses on developing innovative therapeutics, with a current emphasis on metabolic diseases such as obesity. The group advances small-molecule drug candidates targeting high-growth segments of the global pharmaceutical market, aiming to capture demand for next-generation GLP-1 receptor agonists.
Average Trading Volume: 3,070,477
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.63B
For a thorough assessment of 1672 stock, go to TipRanks’ Stock Analysis page.